Harmony Biosciences (NASDAQ:HRMY) Releases Earnings Results, Beats Expectations By $0.19 EPS

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) posted its earnings results on Tuesday. The company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.59 by $0.19, Zacks reports. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm had revenue of $184.73 million for the quarter, compared to the consensus estimate of $184.26 million. During the same period last year, the firm posted $0.67 EPS. The company's revenue was up 19.5% on a year-over-year basis. Harmony Biosciences updated its FY 2025 guidance to EPS.

Harmony Biosciences Stock Performance

Shares of HRMY stock traded up $0.13 during trading hours on Friday, reaching $34.22. 60,338 shares of the company's stock were exchanged, compared to its average volume of 682,272. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. Harmony Biosciences has a 1 year low of $26.47 and a 1 year high of $41.61. The company has a market cap of $1.97 billion, a P/E ratio of 16.22, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82. The company's 50 day moving average is $31.35 and its two-hundred day moving average is $34.01.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on HRMY. UBS Group cut their target price on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a research report on Monday, April 28th. HC Wainwright reiterated a "buy" rating and set a $70.00 price target on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Deutsche Bank Aktiengesellschaft started coverage on shares of Harmony Biosciences in a research note on Tuesday, February 11th. They issued a "buy" rating and a $55.00 price objective on the stock. Mizuho increased their target price on shares of Harmony Biosciences from $42.00 to $44.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 18th. Finally, Needham & Company LLC restated a "buy" rating and issued a $49.00 price target on shares of Harmony Biosciences in a research report on Tuesday. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, Harmony Biosciences currently has an average rating of "Buy" and a consensus target price of $52.33.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.